Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth
Cancer Letters · 2024-06 · 591 · 216879
DOI: 10.1016/j.canlet.2024.216879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-06. Verfasst von Alberto Rivera-Ramos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; Departamento de Bioquí…. Hauptthemen laut MEDLINE: Brain Neoplasms, Cell Movement, Cell Proliferation, Galectin 3. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: España Ministerio de Ciencia Innovación y Universidades, Instituto de Salud Carlos III, Junta de Andalucia Consejeria de Economia Innovacion y Ciencia.
Abstract (Originalsprache)
Galectin-3 (Gal-3) is a multifunctional protein that plays a pivotal role in the initiation and progression of various central nervous system diseases, including cancer. Although the involvement of Gal-3 in tumour progression, resistance to treatment and immunosuppression has long been studied in different cancer types, mainly outside the central nervous system, its elevated expression in myeloid and glial cells underscores its profound impact on the brain's immune response. In this context, microglia and infiltrating macrophages, the predominant non-cancerous cells within the tumour microenvironment, play critical roles in establishing an immunosuppressive milieu in diverse brain tumours. Through the utilisation of primary cell cultures and immortalised microglial cell lines, we have elucidated the central role of Gal-3 in promoting cancer cell migration, invasion, and an immunosuppressive microglial phenotypic activation. Furthermore, employing two distinct in vivo models encompassing primary (glioblastoma) and secondary brain tumours (breast cancer brain metastasis), our histological and transcriptomic analysis show that Gal-3 depletion triggers a robust pro-inflammatory response within the tumour microenvironment, notably based on interferon-related pathways. Interestingly, this response is prominently observed in tumour-associated microglia and macrophages (TAMs), resulting in the suppression of cancer cells growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevill…
- Experimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Förderung
- España Ministerio de Ciencia Innovación y Universidades
- Instituto de Salud Carlos III
- Junta de Andalucia Consejeria de Economia Innovacion y Ciencia
- Horizon 2020 MSCA
- Xarxa de Bancs de Tumors de Catalunya
- Maryland Society of Surveyors
- Ministerio de Ciencia e Innovación
Zitieren
APA
Rivera-Ramos, A., Cruz-Hernández, L., Talaverón, R., Sánchez-Montero, M. T., García-Revilla, J., Mulero-Acevedo, M., Deierborg, T., Venero, J. L., & Sarmiento Soto, M. (2024). Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth. Cancer Letters, 591, 216879. https://doi.org/10.1016/j.canlet.2024.216879
Vancouver
Rivera-Ramos A, Cruz-Hernández L, Talaverón R, Sánchez-Montero MT, García-Revilla J, Mulero-Acevedo M, et al. Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth. Cancer Letters. 2024;591:216879. doi:10.1016/j.canlet.2024.216879
BibTeX
@article{RiveraRamos2024,
author = {Rivera-Ramos, Alberto and Cruz-Hernández, Luis and Talaverón, Rocío and Sánchez-Montero, María Teresa and García-Revilla, Juan and Mulero-Acevedo, Marta and Deierborg, Tomas and Venero, José Luis and Sarmiento Soto, Manuel},
title = {Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth},
journal = {Cancer Letters},
year = {2024},
volume = {591},
pages = {216879},
doi = {10.1016/j.canlet.2024.216879}
}
EUVIMED